


Claims

1. A compound of formula (I)



(I)

wherein

5 R¹ is C₁₋₆-alkyl;

X is selected from

i) -NH-, and

ii) -O-;

R² is selected from

10 iii) H,

iv) cyano, and

v) halogen;

R³ is selected from

vi) NR⁴R⁵, and

15 vii) CHR⁶R⁷;

R⁴ is selected from

viii) C₁₋₆-alkyl,

ix) C₃₋₈-cycloalkyl, and

x) C₃₋₈-cycloalkyl-C₁₋₆-alkyl;

20 R⁵ is selected from

- xi) C₁₋₆-alkyl,
- xii) C₃₋₈-cycloalkyl, and
- xiii) C₃₋₈-cycloalkyl-C₁₋₆-alkyl;

5 or R⁴ and R⁵ together with the nitrogen atom to which they are attached form an heterocycloalkyl optionally substituted with R⁸, wherein the heterocycloalkyl is selected from pyrrolidinyl and piperidinyl;

R⁶ is selected from

- xiv) C₁₋₆-alkyl,
- xv) C₃₋₈-cycloalkyl, and
- 10 xvi) C₃₋₈-cycloalkyl-C₁₋₆-alkyl;

R⁷ is selected from

- xvii) C₁₋₆-alkyl,
- xviii) C₃₋₈-cycloalkyl, and
- xix) C₃₋₈-cycloalkyl-C₁₋₆-alkyl;

15 or R⁶ and R⁷ together with the carbon atom to which they are attached form a C₃₋₈-cycloalkyl optionally substituted with R⁸;

R⁸ is halogen;

with the proviso that N-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide is excluded

20 or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1, wherein

R¹ is C₁₋₆-alkyl;

X is selected from

- i) -NH-, and
- 25 ii) -O-;

R² is selected from

- iii) H, and
- iv) halogen;

R³ is selected from

- 5 v) NR⁴R⁵, and
- vi) CHR⁶R⁷;

R⁴ is selected from

- vii) C₁₋₆-alkyl,
- viii) C₃₋₈-cycloalkyl, and
- 10 ix) C₃₋₈-cycloalkyl-C₁₋₆-alkyl;

R⁵ is selected from

- x) C₁₋₆-alkyl,
- xi) C₃₋₈-cycloalkyl, and
- xii) C₃₋₈-cycloalkyl-C₁₋₆-alkyl;

- 15 or R⁴ and R⁵ together with the nitrogen atom to which they are attached form an heterocycloalkyl optionally substituted with R⁸, wherein the heterocycloalkyl is selected from pyrrolidinyl and piperidinyl;

R⁶ is selected from

- xiii) C₁₋₆-alkyl,
- 20 xiv) C₃₋₈-cycloalkyl, and
- xv) C₃₋₈-cycloalkyl-C₁₋₆-alkyl;

R⁷ is selected from

- xvi) C₁₋₆-alkyl,
- xvii) C₃₋₈-cycloalkyl, and

xviii) C₃₋₈-cycloalkyl-C₁₋₆-alkyl;

or R⁶ and R⁷ together with the carbon atom to which they are attached form a cyclopentyl or a cyclohexyl ring optionally substituted with R⁸;

R⁸ is halogen;

5 with the proviso that (3R)-N-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide is excluded

or a pharmaceutically acceptable salt thereof.

3. A compound according to claim 1 or 2, wherein

R¹ is methyl;

10 X is selected from

i) -NH-, and

ii) -O-;

R² is selected from

iii) H,

15 iv) chloro, and

v) fluoro;

R³ is selected from

vi) NR⁴R⁵, and

vii) CHR⁶R⁷;

20 R⁴ is selected from

viii) methyl,

ix) ethyl,

x) propyl,

xi) cyclopropyl, and

25 xii) cyclopropylmethyl;

R⁵ is selected from

- xiii) methyl,
- xiv) ethyl,
- xv) propyl,
- 5 xvi) cyclopropyl, and
- xvii) cyclopropylmethyl;

or R⁴ and R⁵ together with the nitrogen atom to which they are attached form an heterocycloalkyl optionally substituted with R⁸, wherein the heterocycloalkyl is selected from pyrrolidinyl and piperidinyl;

10 R⁶ is selected from

- xviii) methyl,
- xix) ethyl,
- xx) propyl,
- xxi) cyclopropyl, and
- 15 xxii) cyclopropylmethyl;

R⁷ is selected from

- xxiii) methyl,
- xxiv) ethyl,
- xxv) propyl,
- 20 xxvi) cyclopropyl, and
- xxvii) cyclopropylmethyl;

or R⁶ and R⁷ together with the carbon atom to which they are attached form a cyclopentyl or a cyclohexyl ring optionally substituted with R⁸;

R⁸ is fluoro;

with the proviso that (3R)-N-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide is excluded

or a pharmaceutically acceptable salt thereof.

4. A compound according to any one of claims 1 to 3, wherein R² is selected from
 - 5 i) H,
 - ii) chloro, and
 - iii) fluoro.
5. A compound according to any one of claims 1 to 4, wherein R⁴ is methyl.
6. A compound according to any one of claims 1 to 5, wherein R⁵ is ethyl.
- 10 7. A compound according to any one of claims 1 to 6, wherein R⁴ and R⁵ together with the nitrogen atom to which they are attached form an heterocycloalkyl optionally substituted with R⁸, wherein the heterocycloalkyl is selected from pyrrolidinyl and piperidinyl.
8. A compound according to any one of claims 1 to 7, wherein R⁴ and R⁵ together with the nitrogen atom to which they are attached form an unsubstituted heterocycloalkyl, wherein
15 the heterocycloalkyl is pyrrolidinyl.
9. A compound according to any one of claims 1 to 8, wherein R⁶ and R⁷ are independently selected from
 - i) methyl,
 - ii) ethyl,
 - 20 iii) propyl,
 - iv) cyclopropyl, and
 - v) cyclopropylmethyl.
10. A compound according to any one of claims 1 to 9, wherein R⁶ and R⁷ together with the nitrogen atom to which they are attached form a cyclopentyl or a cyclohexyl ring.
- 25 11. A compound according to any one of claims 1 to 10, wherein R⁸ is fluoro.

12. A compound according to any one of claims 1 to 11, wherein the compound is selected from
- 6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluoro-phenoxy]-3-methyl-4-oxo-quinazoline;
- 5 6-[6-chloro-2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]phenoxy]-3-methyl-4-oxo-quinazoline;
- (3R)-N-[4-chloro-2-cyano-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide;
- N-[4-chloro-2-cyano-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]pyrrolidine-1-sulfonamide;
- 10 6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]phenoxy]-3-methyl-4-oxo-quinazoline;
- N-[2-cyano-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]pyrrolidine-1-sulfonamide;
- (3R)-N-[2-cyano-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide;
- N-[2-cyano-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]cyclopentanesulfonamide;
- 15 N-[2-cyano-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]cyclohexanesulfonamide;
- N-[2-cyano-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]butane-2-sulfonamide;
- 6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]anilino]-3-methyl-4-oxo-quinazoline;
- (3R)-N-[2-cyano-3-[(3-methyl-4-oxo-quinazolin-6-yl)amino]phenyl]-3-fluoro-pyrrolidine-1-sulfonamide;
- 20 6-[6-chloro-2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]anilino]-3-methyl-4-oxo-quinazoline;
- N-[4-chloro-2-cyano-3-[(3-methyl-4-oxo-quinazolin-6-yl)amino]phenyl]pyrrolidine-1-sulfonamide;
- N-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]pyrrolidine-1-sulfonamide;
- 25

N-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]cyclopentanesulfonamide; and

6-[2-cyano-3-(dimethylsulfamoylamino)-6-fluoro-phenoxy]-3-methyl-4-oxo-quinazoline;

or a pharmaceutically acceptable salt thereof.

- 5 13. A compound according to any one of claims 1 to 12, wherein the compound is selected from

6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluoro-phenoxy]-3-methyl-4-oxo-quinazoline;

6-[6-chloro-2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]phenoxy]-3-methyl-4-oxo-quinazoline;

- 10 N-[4-chloro-2-cyano-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]pyrrolidine-1-sulfonamide;

6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]phenoxy]-3-methyl-4-oxo-quinazoline;

N-[2-cyano-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]pyrrolidine-1-sulfonamide;

N-[2-cyano-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]cyclopentanesulfonamide;

- 15 N-[2-cyano-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]cyclohexanesulfonamide;

N-[2-cyano-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]butane-2-sulfonamide;

6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]anilino]-3-methyl-4-oxo-quinazoline;

6-[6-chloro-2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]anilino]-3-methyl-4-oxo-quinazoline;

- 20 N-[4-chloro-2-cyano-3-[(3-methyl-4-oxo-quinazolin-6-yl)amino]phenyl]pyrrolidine-1-sulfonamide;

N-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]pyrrolidine-1-sulfonamide;

- 25 N-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]cyclopentanesulfonamide; and

6-[2-cyano-3-(dimethylsulfamoylamino)-6-fluoro-phenoxy]-3-methyl-4-oxo-quinazoline;

or a pharmaceutically acceptable salt thereof.

14. A compound according to any one of claims 1 to 13 for use as therapeutically active substance.
- 5 15. A pharmaceutical composition comprising a compound according to any one of claims 1 to 13 and a therapeutically inert carrier.
16. A compound according to any one of claims 1 to 13 for use in the treatment or prophylaxis of thyroid cancer, colorectal cancer, brain cancer, melanoma or NSCLC.
17. The use of a compound according to any one of claims 1 to 13 for the treatment or
10 prophylaxis of thyroid cancer, colorectal cancer, brain cancer, melanoma or NSCLC.
18. The use of a compound according to any one of claims 1 to 13 for the preparation of a medicament for the treatment or prophylaxis of thyroid cancer, colorectal cancer, brain cancer, melanoma or NSCLC.
19. A method for the treatment or prophylaxis of thyroid cancer, colorectal cancer, brain cancer,
15 melanoma or NSCLC, which method comprises administering an effective amount of a compound as defined in any one of claims 1 to 13 to a patient in need thereof.
20. The invention as hereinbefore described.
